Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.56 |
| ▸ | CNR2 | P34972 | 5/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342475 | 0.89 | CNR1 (0.67) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL674935 | 0.83 | GABRA2 (0.67) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL5367435 | 0.82 | CNR1 (0.64) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4501902 | 0.81 | CNR1 (0.65) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4434578 | 0.81 | CNR1 (0.65) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4510387 | 0.80 | CNR1 (0.54) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4479830 | 0.80 | GABRA2 (0.72) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4474828 | 0.79 | CNR1 (0.63) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL6332950 | 0.79 | CNR1 (0.68) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL5370038 | 0.78 | CNR1 (0.62) | CNR1CNR2GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER, INC. | 2007-11-01 | — | — | US | disclosed |
| US-7247628-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1572662-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052864-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885GABRA2 41/4885 |
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885GABRA2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.